Financial PositionWith $17.3M in cash, and a low burn rate, Anixa should have runway into FY27 and through key events generated by its partnerships to unlock investor value.
Patent ProtectionThe United States Patent and Trademark Office is set to issue a patent that covers Anixa Biosciences' breast cancer vaccine technology, extending intellectual property protection into the mid-2040s.
Strategic PartnershipsAnixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensures efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.